Print Friendly Page

Protocol No. AALL1732

Principal Investigator DeSantes, Kenneth

Phase III

Age Group Both

Scope National

Sponsor Type National

Title A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Applicable Disease Sites Leukemia; Lymphoma

Drugs Involved 6-mercaptopurine; 6-mp (6-mercaptopurine); CMC-544 (Inotuzumab ozogamicin); Inotuzumab ozogamicin; adr (doxorubicin); adria (doxorubicin); adriamycin (doxorubicin); ara-c (cytarabine); cerubidine (daunorubicin); cpm (cyclophosphamide); ctx (cyclophosphamide); cyclophosphamide; cytarabine; cytosar (cytarabine); cytosine arabinoside (cytarabine); cytoxan (cyclophosphamide); daunomycin (daunorubicin); daunorubicin; decadron (dexamethasone); dexamethasone; dnm (daunorubicin); dox (doxorubicin); doxorubicin; hdmtx (methotrexate); it-mtx (methotrexate); leucovorin; leukovorin (leucovorin); lv (leucovorin); methotrexate; mtx (methotrexate); neosar (cyclophosphamide); oncovin (vincristine); peg-asparaginase (pegasparaginase); prednisone; rubidamycin (daunorubicin); thioguanine (6-thioguanine); vcr (vincristine); vin (vincristine); vincristine; wellcovorin (leucovorin)

Status Open

Participating Institutions Gundersen Health System; UW Hospital and Clinics